alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › therapeutic-target

therapeutic-target

6 studies tagged therapeutic-target, dated 2019-03-20 to 2024-01-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Quantification of COX-2 Level in Alzheimer's Disease Patients to Develop Potential Blood-Based Biomarker for Early Diagnosis and Therapeutic Target 2024-01-01
  2. Cis P-tau is a central circulating and placental etiologic driver and therapeutic target of preeclampsia 2023-09-05
  3. miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease 2023-01-01

Studies

6 studies carry this tag.

Date range

2019 to 2024

Top journals

  • Journal of Alzheimer's disease : JAD 3
  • BMC medicine 1
  • Journal of immunology (Baltimore, Md. : 1950) 1
  • Nature communications 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Quantification of COX-2 Level in Alzheimer's Disease Patients to Develop Potential Blood-Based Biomarker for Early Diagnosis and Therapeutic Target

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2024-01-01 Biomarkers

    It can be concluded that COX-2 protein can serve as a potential blood-based biomarker for early detection and can be a good platform for therapeutic intervention for AD.

  2. Cis P-tau is a central circulating and placental etiologic driver and therapeutic target of preeclampsia

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Nature communications 2023-09-05 Biomarkers

    Preeclampsia (PE) is the leading cause of maternal and fetal mortality globally and may trigger dementia later in life in mothers and their offspring.

  3. miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01 Biomarkers

    Alzheimer's disease (AD) is a cumulative progressive neurodegenerative disease characterized mainly by impairment in cognitive functions accompanied by memory loss, disturbance in behavior and personality, and difficulties in learning.

  4. Circulatory GSK-3β: Blood-Based Biomarker and Therapeutic Target for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer's disease : JAD 2022-01-01 Biomarkers

    These proteins can serve as potential blood markers for the diagnosis of AD and EO can suppress their level.

  5. Complement-Mediated Events in Alzheimer's Disease: Mechanisms and Potential Therapeutic Targets

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of immunology (Baltimore, Md. : 1950) 2020-01-01 Genetics

    An estimated 5.7 million Americans suffer from Alzheimer's disease in the United States, with no disease-modifying treatments to prevent or treat cognitive deficits associated with the disease.

  6. ApoE4: an emerging therapeutic target for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. BMC medicine 2019-03-20 Genetics

    ApoE4 is a promising AD therapeutic target that remains understudied.

All topic tags with their study counts